What is the address of AM-PHARMA?

The registered office of AM-PHARMA is located at Dronckaertstraat 618, 8930 Menen.

Is AM-PHARMA still active?

Yes. According to the CBE (30 October 2026) AM-PHARMA is active, legal situation “Normale toestand”, started on 22 September 2010.

Is AM-PHARMA registered on Peppol?

Yes, AM-PHARMA is registered on the Peppol network with ID 0208:0829559341.

What is the enterprise number of AM-PHARMA?

The enterprise number of AM-PHARMA is BE0829559341.

When was AM-PHARMA founded?

AM-PHARMA was founded on 22 September 2010.

Who are the directors of AM-PHARMA?

According to the 2025 annual accounts, the directors of AM-PHARMA are: Katrien Adriaen.

Is AM-PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 September 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did AM-PHARMA make in 2025?

AM-PHARMA recorded a loss after taxes of € 38,840 in financial year 2025.

What is the revenue of AM-PHARMA?

As a small company, AM-PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -9,314.

How many employees does AM-PHARMA have?

According to the 2025 annual accounts, AM-PHARMA has 0 full-time equivalents (FTE).

AM-PHARMA (Private Limited) - Menen - BE0829559341

Q: What does AM-PHARMA do?

AM-PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 22 September 2010, 1 establishment.

Dossier AM-PHARMA, printed on 30 October 2026 from databakkes.be/en/0829559341/am-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

AM-PHARMA from Menen, company number BE0829559341, closed financial year 2025 with a result of € -38,840 after tax. For that financial year AM-PHARMA recorded a gross margin of € -9,314 and equity of € 493,393. Compared with financial year 2024, the result moved from € 54,476 to € -38,840. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Healthy

€ 493,393

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -38,840

▼ still € 54,476 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,930

▼ 26% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 343,393.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 159,936

▼ 30% vs 2024

€ 19,895 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 2,009

▲ 5% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 7,244

▼ 26% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 101,756 Gross margin 2022: € 101,756 First fiscal year in the series	€ 108,309 Gross margin 2023: € 108,309 ▲ 6% vs 2022 (€ 101,756) Favourable step	€ 106,052 Gross margin 2024: € 106,052 ▼ 2% vs 2023 (€ 108,309) Unfavourable step	€ -9,314 Gross margin 2025: € -9,314 ▼ € 115,366 vs 2024 (€ 106,052) Unfavourable step	▼ € 115,366
Profit after taxes	€ 52,172 Profit after taxes 2022: € 52,172 First fiscal year in the series	€ 56,219 Profit after taxes 2023: € 56,219 ▲ 8% vs 2022 (€ 52,172) Favourable step	€ 54,476 Profit after taxes 2024: € 54,476 ▼ 3% vs 2023 (€ 56,219) Unfavourable step	€ -38,840 Profit after taxes 2025: € -38,840 ▼ € 93,316 vs 2024 (€ 54,476) Unfavourable step	▼ € 93,316
Equity	€ 424,922 Equity 2022: € 424,922 First fiscal year in the series	€ 479,475 Equity 2023: € 479,475 ▲ 13% vs 2022 (€ 424,922) Favourable step	€ 532,233 Equity 2024: € 532,233 ▲ 11% vs 2023 (€ 479,475) Favourable step	€ 493,393 Equity 2025: € 493,393 ▼ 7% vs 2024 (€ 532,233) Unfavourable step	▼ 7%
Total debts	€ 1,005,274 Total debts 2022: € 1,005,274 First fiscal year in the series	€ 941,719 Total debts 2023: € 941,719 ▼ 6% vs 2022 (€ 1,005,274) Favourable step	€ 889,793 Total debts 2024: € 889,793 ▼ 6% vs 2023 (€ 941,719) Favourable step	€ 926,769 Total debts 2025: € 926,769 ▲ 4% vs 2024 (€ 889,793) Unfavourable step	▲ 4%
Cash	€ 4,932 Cash 2022: € 4,932 First fiscal year in the series	€ 3,563 Cash 2023: € 3,563 ▼ 28% vs 2022 (€ 4,932) Unfavourable step	€ 5,344 Cash 2024: € 5,344 ▲ 50% vs 2023 (€ 3,563) Favourable step	€ 3,930 Cash 2025: € 3,930 ▼ 26% vs 2024 (€ 5,344) Unfavourable step	▼ 26%
Retained profit	€ 274,922 Retained profit 2022: € 274,922 First fiscal year in the series	€ 329,475 Retained profit 2023: € 329,475 ▲ 20% vs 2022 (€ 274,922) Favourable step	€ 382,233 Retained profit 2024: € 382,233 ▲ 16% vs 2023 (€ 329,475) Favourable step	€ 343,393 Retained profit 2025: € 343,393 ▼ 10% vs 2024 (€ 382,233) Unfavourable step	▼ 10%
Dividend	€ 1,600 Dividend 2022: € 1,600 First fiscal year in the series	€ 1,666 Dividend 2023: € 1,666 ▲ 4% vs 2022 (€ 1,600) Unchanged	€ 1,718 Dividend 2024: € 1,718 ▲ 3% vs 2023 (€ 1,666) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 1,718) Unchanged	▼ 100%
Bank debt	€ 367,103 Bank debt 2022: € 367,103 First fiscal year in the series	€ 299,659 Bank debt 2023: € 299,659 ▼ 18% vs 2022 (€ 367,103) Favourable step	€ 229,622 Bank debt 2024: € 229,622 ▼ 23% vs 2023 (€ 299,659) Favourable step	€ 159,936 Bank debt 2025: € 159,936 ▼ 30% vs 2024 (€ 229,622) Favourable step	▼ 30%
Balance sheet total	€ 1,430,196 Balance sheet total 2022: € 1,430,196 First fiscal year in the series	€ 1,421,194 Balance sheet total 2023: € 1,421,194 ▼ 1% vs 2022 (€ 1,430,196) Unchanged	€ 1,422,026 Balance sheet total 2024: € 1,422,026 Unchanged (€ 1,421,194) Unchanged	€ 1,420,162 Balance sheet total 2025: € 1,420,162 Unchanged (€ 1,422,026) Unchanged

Key figures of AM-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AM-PHARMA?

What happened at AM-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: loss of € 38,840 (▼ € 93,316 vs 2024). Source: NBB ↗
Oct 13, 2010 New establishment in Menen. KBO
2010 Katrien Adriaen became a director. NBB
Sep 22, 2010 Start of the company according to the CBE. KBO

In short

From € 52,172 profit in 2022 to € 38,840 loss in 2025.

Paid € 42,360 in corporate taxes since 2022.

Best year ever: 2023, with € 56,219 profit.

Paid out € 4,984 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Katrien Adriaen

AM-PHARMA

Apotheek De Plaats BV 99%

Behind AM-PHARMA is Katrien Adriaen. It owns 99% of Apotheek De Plaats BV itself.

Directors

According to the 2025 annual accounts

Katrien Adriaen

Director

Also active at: apotheek de plaats

since 2010

Establishments

Establishment units

Physical locations of this company

Registered office

Dronckaertstraat 618

8930 Menen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

ADRIMAR

€ 207,149 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0829.559.341

VAT number

BE 0829.559.341

Registered office

Dronckaertstraat 618, 8930 Menen

Names & denominations

AM-PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 September 2010

Peppol

Active · Active since 25 Jan 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

AM-PHARMA

Warning lights

Financials

What happened to AM-PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions